COMPANY

Thymmune Therapeutics

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1M (SBIR Phase II 5R44AI170266-05, continuation, notice Jun 5, 2026). NIH RePORTER 5R44AI170266-05 (Jun 5, 2026)
Evidence (1 event)
- Jun 5, 2026 · NIH RePORTER 5R44AI170266-05
  Organization: THYMMUNE THERAPEUTICS, INC; City/State: CAMBRIDGE, MA; Project number: 5R44AI170266-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-05; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a stem-cell derived thymic cell therapy to treat patients with athymia; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jun 5, 2026 Grant Government grant — SBIR: $1M (annual award, as published), announced Jun 5, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 28, 2025 Grant Government grant — SBIR: $1M (annual award, as published), announced Apr 28, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Last 2 years.

Jun 5, 2026 Government grant — SBIR: $1M (annual award, as published), announced Jun 5, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 28, 2025 Government grant — SBIR: $1M (annual award, as published), announced Apr 28, 2025. Agency: NIH/NIAID. Source: government award database. source ↗